首页> 外文期刊>AJNR. American journal of neuroradiology >Intrasinus catheter-directed heparin infusion in the treatment of dural venous sinus thrombosis.
【24h】

Intrasinus catheter-directed heparin infusion in the treatment of dural venous sinus thrombosis.

机译:鼻内导管定向肝素输注治疗硬脑膜静脉窦血栓形成。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE: In this small series, local intrasinus catheter-directed heparin infusion with or without balloon thrombectomy was safe in the treatment of dural venous sinus thrombosis (DVST). Although systemic anticoagulation (SAC) is the treatment of choice, there is a lack of consensus regarding the best treatment should SAC fail or be contraindicated. We present our institutional experience with 16 patients in whom failure of, or contraindication to, SAC occurred and who subsequently underwent intrasinus catheter-directed heparin infusion with or without balloon thrombectomy. MATERIALS AND METHODS: A retrospective review of 16 patients ranging in age from 14 days to 77 years who had intrasinus catheter-directed heparin infusion was undertaken with 9 male and 7 female patients identified. Of these 16 patients, 4 (25%) had a contraindication to SAC and SAC failed in 12 (75%). Technically successful intrasinus infusion catheter placement was achieved in all 16 patients (100%). Mean duration of infusion was 3.3 days (range, 1-6 days). Adjunctive balloon thrombectomy was performed in 9 (56.3%) of 16 patients. No procedure-related mortality occurred. RESULTS: Partial and complete sinus recanalization occurred in 10 (62.5%) of 16 patients and 1 (6.3%) of 16 patients, respectively. There were 3 deaths (18.8%) attributed to disease progression. At most recent clinical follow-up (mean, 9.3 months), 11 (84.6%) of 13 surviving patients were independent, with a modified Rankin Scale (mRS) score of 1 or less. CONCLUSIONS: Local intrasinus catheter-directed heparin infusion with or without adjunctive balloon thrombectomy seems to be a safe and effective treatment of DVST in patients in whom SAC failed or in whom there was a contraindication to SAC. In addition, the risk for symptomatic intracranial hemorrhage may be significantly lower than intrasinus infusion of thrombolytics.
机译:背景与目的:在这个小系列研究中,在有或没有进行球囊血栓切除术的情况下,在局部窦内导管引导下进行肝素输注对于治疗硬脑膜静脉窦血栓形成(DVST)是安全的。尽管系统性抗凝(SAC)是首选治疗方法,但如果SAC失败或禁忌,则关于最佳治疗方法尚无共识。我们介绍了16位SAC失败或禁忌的患者的机构经验,这些患者随后接受了窦内导管定向肝素输注或不行球囊血栓切除术。材料与方法:回顾性分析了16例年龄在14天至77岁之间的患者,他们接受了窦内导管定向肝素输注,其中9例男性和7例女性患者。在这16例患者中,有4例(25%)有SAC禁忌症,而12例SAC失败(75%)。所有16例患者(100%)均取得了技术上成功的鼻窦输液导管放置。平均输注时间为3.3天(1-6天)。 16例患者中有9例(56.3%)进行了辅助性球囊血栓切除术。没有发生与手术相关的死亡率。结果:部分和完全窦再通发生在16例患者中的10例(62.5%)和16例患者中的1例(6.3%)。疾病进展导致3例死亡(18.8%)。在最近的临床随访(平均9.3个月)中,有13例幸存患者中有11例(84.6%)是独立的,经修订的兰金量表(mRS)评分为1或更低。结论:对于SAC失败或SAC有禁忌症的患者,局部窦内导管定向肝素输注或不行辅助性球囊血栓切除术似乎是一种安全有效的DVST治疗方法。此外,有症状的颅内出血的风险可能明显低于窦内输注溶栓剂的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号